PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.82%
G&A reduction while AXSM shows 0.00% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
-166.83%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-35.81%
Operating expenses reduction while AXSM shows 6.62% growth. Joel Greenblatt would examine advantage.
-35.81%
Total costs reduction while AXSM shows 8.31% growth. Joel Greenblatt would examine advantage.
1.74%
Interest expense growth less than half of AXSM's 24.56%. David Dodd would verify sustainability.
-142558.33%
Both companies reducing D&A. Martin Whitman would check industry patterns.
-488.78%
EBITDA decline while AXSM shows 35.57% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
36.41%
Similar operating income growth to AXSM's 35.57%. Walter Schloss would investigate industry trends.
No Data
No Data available this quarter, please select a different quarter.
2042.35%
Other expenses growth while AXSM reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
4.49%
Tax expense change of 4.49% while AXSM maintains burden. Bruce Berkowitz would investigate strategy.
439.57%
Net income growth exceeding 1.5x AXSM's 19.26%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
440.81%
EPS growth exceeding 1.5x AXSM's 20.49%. David Dodd would verify competitive advantages.
440.81%
Diluted EPS growth exceeding 1.5x AXSM's 20.49%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.